Literature DB >> 7834752

Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses.

W C Sha1, H C Liou, E I Tuomanen, D Baltimore.   

Abstract

NF-kappa B, a heterodimeric transcription factor composed of p50 and p65 subunits, can be activated in many cell types and is thought to regulate a wide variety of genes involved in immune function and development. Mice lacking the p50 subunit of NF-kappa B show no developmental abnormalities, but exhibit multifocal defects in immune responses involving B lymphocytes and nonspecific responses to infection. B cells do not proliferate in response to bacterial lipopolysaccharide and are defective in basal and specific antibody production. Mice lacking p50 are unable effectively to clear L. monocytogenes and are more susceptible to infection with S. pneumoniae, but are more resistant to infection with murine encephalomyocarditis virus. These data support the role of NF-kappa B as a vital transcription factor for both specific and nonspecific immune responses, but do not indicate a developmental role for the factor.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7834752     DOI: 10.1016/0092-8674(95)90415-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  368 in total

1.  NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

Authors:  D C Guttridge; C Albanese; J Y Reuther; R G Pestell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

Review 2.  NF-kappaB and apoptosis in mammary epithelial cells.

Authors:  R W Clarkson; C J Watson
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

3.  Nature of the retrograde signal from injured nerves that induces interleukin-6 mRNA in neurons.

Authors:  P G Murphy; L S Borthwick; R S Johnston; G Kuchel; P M Richardson
Journal:  J Neurosci       Date:  1999-05-15       Impact factor: 6.167

4.  RelB nuclear translocation regulates B cell MHC molecule, CD40 expression, and antigen-presenting cell function.

Authors:  B J O'Sullivan; K P MacDonald; A R Pettit; R Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

5.  Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes.

Authors:  Hajir Dadgostar; Brian Zarnegar; Alexander Hoffmann; Xiao-Feng Qin; Uyen Truong; Govinda Rao; David Baltimore; Genhong Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

6.  Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes.

Authors:  N H Purcell; G Tang; C Yu; F Mercurio; J A DiDonato; A Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 7.  Toll-like receptors: molecular mechanisms of the mammalian immune response.

Authors:  H D Brightbill; R L Modlin
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

Review 8.  Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention.

Authors:  J Panés; M Perry; D N Granger
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

9.  Novel nonsense gain-of-function NFKB2 mutations associated with a combined immunodeficiency phenotype.

Authors:  Hye Sun Kuehn; Julie E Niemela; Karthik Sreedhara; Jennifer L Stoddard; Jennifer Grossman; Christian A Wysocki; M Teresa de la Morena; Mary Garofalo; Jingga Inlora; Michael P Snyder; David B Lewis; Constantine A Stratakis; Thomas A Fleisher; Sergio D Rosenzweig
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

10.  NF-κB p50 (nfkb1) contributes to pathogenesis in the Eμ-TCL1 mouse model of chronic lymphocytic leukemia.

Authors:  Timothy L Chen; Minh Tran; Aparna Lakshmanan; Bonnie K Harrington; Nikhil Gupta; Virginia M Goettl; Amy M Lehman; Stephen Trudeau; David M Lucas; Amy J Johnson; John C Byrd; Erin Hertlein
Journal:  Blood       Date:  2017-05-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.